Immunovant, Inc. (IMVT) Earnings Call Transcripts
Immunovant, Inc.'s Latest Earnings Call - April 2, 2026
In the fiscal quarter ending March 31, 2026, Immunovant, Inc. announced significant developments regarding its drug Brepocitinib and the disappointing results from the Batoclimab Phase III study in Thyroid Eye Disease (TED). The company is expanding Brepocitinib's indications to include Lichen Planopilaris (LPP), with a Phase IIb/III trial now underway, reflecting a strategic pivot towards high unmet needs in dermatology. While the Batoclimab study failed to meet its primary endpoint, management expressed optimism about the implications for Graves' disease treatment, citing a 75% mean IgG reduction in hyperthyroid patients. Overall, the company remains focused on advancing its pipeline, with multiple catalysts expected in the coming year.
Reported metrics
| Metric | Value |
|---|---|
| LPP Patient Population Size | 100,000 (positive) |
| IgG Reduction in Hyperthyroid Patients | 75% (positive) |
| Brepocitinib Phase IIb/III Trial Enrollment | 72 patients in Phase IIb, 270 in Phase III (positive) |
| Primary Endpoint for Batoclimab Study | Did not meet (negative) |
| Proptosis Responder Rate in TED | 20-30% (negative) |
| Expected Readouts in 2027 | Multiple (positive) |
Guidance from management
Management expressed optimism about the potential of Brepocitinib in LPP and Graves' disease, indicating that they are committed to advancing their pipeline efficiently. They are not ready to provide specific timelines but expect to share more data as it becomes available.
What analysts pressed on
Analysts expressed concerns regarding the implications of the Batoclimab failure on the perception of Immunovant's pipeline, particularly regarding the overlap with Graves' disease. There were also questions about the enrollment strategy and the potential for transitioning TED sites to the Graves program.
Main topics on the call
- Expansion into Lichen Planopilaris (LPP) — Immunovant is initiating a Phase IIb/III trial for Brepocitinib in treating LPP, a severe inflammatory scalp disorder with no FDA-approved therapies. Management stated, "This is a disease with tremendous high unmet need,...
- Disappointing Batoclimab Results — The Phase III study for Batoclimab in TED did not meet its primary endpoint, which management acknowledged as disappointing. However, they noted that the study provided valuable insights for ongoing and future programs, ...
- Positive IgG Suppression Data — In the TED study, a 75% mean IgG reduction was observed in hyperthyroid patients, which management believes supports the efficacy of their approach in Graves' disease. They noted, "We expect to show benefit in the Graves...
- Continuous Enrollment Strategy — Immunovant plans to enroll patients in the Phase III portion of the LPP study concurrently with the Phase IIb results, indicating a streamlined development approach. Management emphasized, "We are not viewing this as a r...
Read the full Immunovant, Inc. transcript (April 2, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Immunovant, Inc.
Immunovant, Inc. (IMVT) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 27 calls on record spanning March 30, 2020 to August 6, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 27 Immunovant, Inc. earnings call transcripts on record, spanning March 30, 2020 to August 6, 2026. Based on this history, Immunovant, Inc. reports quarterly. The most recent call on file is dated August 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- IMVT
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 27
- First call
- March 30, 2020
- Most recent
- August 6, 2026
- Reporting cadence
- quarterly